FDA warns about unapproved medications from a Canadian supplier

.

FDA warns about unapproved medications from a Canadian supplier

The U. S. Food & Drug Administration (FDA) has warned more than 350 medical practices that they might have received unapproved, counterfeit or unsafe medications from a Canadian supplier.

The federal food and drugs regulator said that the medications, including unapproved variants of Botox, could harm patients as they could be counterfeit or contaminated.

The foreign supplier who allegedly supplied the unapproved medications to the U. S. medical practices is operated by Canada Drugs, which is also called Quality Specialty Products (QSP), QP Medical or Bridgewater Medical.

In the letter written to the medical practices, the federal agency said, "FDA is very concerned that products distributed by these suppliers may cause harm to patients, because they may be unsafe or ineffective."

The FDA also warned doctors about purchasing drugs from any source other than pharmacies licensed by the U. S. authorities.

Dr. Peter B. Fodor, a plastic surgeon and an expert on Botox, also warned that using a non-FDA approved Botox could be very dangerous.

This is the fifth warning issued by the FDA this year about a foreign supplier supplying unapproved medications.

 


Latest News

Though Wages in Japan Increase But It’s not Enough to Beat Inflation
Jack Ma Prepares for Second Alibaba IPO
RBA Feels Currency Overrated: Keeps Record Low Benchmark Rate
U.S. Business Lobby Express Concerns Saying Antitrust Probes in China Unfair
First dengue fever outbreak in 70 years in Japan
Rise in skin cancer due to cheap holidays
Cardio and wine is a great combination
Surrogacy is a form of exploitation: Ekman
Cuba Trims Down on Amount of Goods Which can be Carried by Travellers
Barclays Will Sell Its Spanish Businesses To CaixaBank In a Deal of 800 Million
Withdrawal in China’s Purchasing Managers' Index Amplifies Calls for Policy Easi
The Ukraine Mayhem Leads Euro to a Fresh One Year Low